Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. - Wikidata - wikimedia - TriplyDB

Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.

Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.

http://www.wikidata.org/entity/Q33826258

about

New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law Cancer and liver cirrhosis: implications on prognosis and management Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma.Hepatitis C virus-induced hepatocellular carcinoma The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib.Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.Hagen-Poiseuille's law: The link between cirrhosis, liver stiffness, portal hypertension and hepatic decompensation.Novel treatment options for portal hypertension.Emerging therapies for portal hypertension in cirrhosis.Angiogenesis and Fibrogenesis in Chronic Liver Diseases.Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study.Microvessel density analysis in patients with viral hepatitis-related hepatocellular carcinoma.The influence of sorafenib on hepatic encephalopathy and the mechanistic survey in cirrhotic rats.Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis.Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development.The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study.Antiangiogenic therapy for portal hypertension in liver cirrhosis: Current progress and perspectives

P2860

Q26772800-9E3BBE3F-B68A-4FCA-8481-EF9F5D51FD91 Q26797581-A183932B-AB47-46F9-9EE8-198D2F1AAE24 Q28068579-62F42B08-58C2-477C-9D38-C7E83F794B1D Q28068710-5C5BFEF3-513A-4DF6-9091-2A087070C685 Q28272678-E87E7CA3-33E1-4EBC-8278-400DF6CAFEC2 Q33584901-BC72AFE2-994F-49C2-BB3B-5F62909D9FCE Q34321931-66D3C067-C146-427A-9212-5564D400F3A1 Q35619104-B0CF1860-90D8-403E-84EB-C4A91A0E331E Q35824057-A55196FB-8962-413B-B707-8C73AD9354B2 Q36929326-7DB9F4F8-19EA-4866-8E34-454101CB6D60 Q37045749-B1F2A4A0-E623-43E8-A15C-303AE7B12B2B Q38201503-EE85A30C-663F-446D-B8F2-24A30B6917E3 Q38334016-72E08DF1-F0D9-4555-B8A3-B83A92762978 Q38680437-A1D7C0F1-550C-4E8A-ABFC-71388053A773 Q38826464-97B7B570-644A-4618-BBC3-D1FF02B33337 Q39140170-16CC43B4-8D57-43E2-9E51-831A52DF9716 Q39643244-B64E6120-9818-4BB0-95D8-5A77F51A9155 Q42172816-187CABC7-9DB5-4B90-836D-9D08CFAD7B89 Q48330765-86B3D150-4AB8-47DA-8A0B-24879805ACDA Q48599791-2761398E-C9B4-47E0-901D-188A26B69EED Q49788208-0EAAD2E8-1284-4B4B-82FC-835AFE9B13FF Q54342105-D3F8BF62-A097-433E-8E82-2B298E6CEBF6 Q58760398-7B2183A0-E8DD-4C0F-976A-188DE6C0B0F2

P2860

Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.

http://www.wikidata.org/entity/Q33826258

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Reversible decrease of portal ...... tive side effect of sorafenib.

@ast

Reversible decrease of portal ...... tive side effect of sorafenib.

@en

type

label

Reversible decrease of portal ...... tive side effect of sorafenib.

@ast

Reversible decrease of portal ...... tive side effect of sorafenib.

@en

prefLabel

Reversible decrease of portal ...... tive side effect of sorafenib.

@ast

Reversible decrease of portal ...... tive side effect of sorafenib.

@en

P1433

Q33826258-BD0DA53D-A034-4AB8-A28F-16923A34B577

P1476

Q33826258-34FA68D2-9283-4934-8826-09A45A1899D1

P2093

Q33826258-4BB4CF8A-2651-413B-A7B4-D45012FE9FB8

Q33826258-4BE51A36-AC60-4365-A35D-9F31F5A283EB

Q33826258-4D8FF310-4773-485B-8E06-2C59CC891EA1

Q33826258-68E5DA86-5469-4254-B349-1A849DD7C6B3

Q33826258-6942D0B9-9517-4AFC-A1F0-0D2ED9991963

Q33826258-7581A5E5-F511-48E2-BDC3-8C45A06A7156

Q33826258-8EE97E86-D435-4A45-896E-6FB3E9B3D3B0

Q33826258-C7008060-06FA-402C-98B0-61148BA0779B

Q33826258-F5D83381-13B7-4E61-B201-8E75AC6A78AE

P2860

Q33826258-21BE4294-0BDB-4421-A529-99C6CDBED3CA

Q33826258-2D4FA974-F41A-474B-9CD0-AE1B2BBC5AD9

Q33826258-305817F1-BBE0-4222-B1A0-686F6C5718CA

Q33826258-39181494-1FB2-4745-A1F6-97B178E279E7

Q33826258-5DE88037-97B7-47A8-8014-9BF2BA90ED11

Q33826258-5E07A148-265C-4BCB-A166-3748F419772F

Q33826258-5E0F696B-F98E-4DC0-96F6-61C7E056F0C7

Q33826258-5F139DD2-4A11-4058-8922-52CED696439E

Q33826258-61DE49B0-738E-49CB-9500-C73694AADD44

Q33826258-658922AD-5EC6-4868-8059-B08F36B5CC4D

P304

Q33826258-BE30681E-FA80-4258-AA8B-1D3E57384192

P31

Q33826258-B3E47EFC-B28D-4878-8555-7423CB5713DB

P356

Q33826258-E2217E80-1C53-4C63-89B8-0104FBE7745B

P407

Q33826258-3ED8F355-915D-4BFE-81A4-BD46C3E7AA5B

P433

Q33826258-13B03E07-5BD5-466F-B611-8A88CD27A9D3

P478

Q33826258-ABC6A0D7-11E4-4CBA-BCC9-BDE8FA6FEAA9

P50

Q33826258-1B531E0A-3825-40A1-B4CB-0A5E2694856B

Q33826258-276CC87E-E49E-479F-ADF6-A04FE2EA59FE

P577

Q33826258-02B6F107-FDBA-458E-9504-5AC19BB3FA7B

P5875

Q33826258-311A7280-2137-4BA4-A905-A8E4F7089024

P698

Q33826258-9E8F85D6-A185-4CD4-875F-257343264E3D

P932

Q33826258-96738F24-A28B-416C-9910-E24201AE9E62

P356

JOURNAL.PONE.0016978

P1433

P1476

Reversible decrease of portal ...... tive side effect of sorafenib.

@en

P2093

Benoit Blanchet

http://www.w3.org/2001/XMLSchema#string

François Goldwasser

http://www.w3.org/2001/XMLSchema#string

Hervé Gouya

http://www.w3.org/2001/XMLSchema#string

Olivier Vignaux

http://www.w3.org/2001/XMLSchema#string

Paul Legmann

http://www.w3.org/2001/XMLSchema#string

Philippe Sogni

http://www.w3.org/2001/XMLSchema#string

Romain Coriat

http://www.w3.org/2001/XMLSchema#string

Stanislas Chaussade

http://www.w3.org/2001/XMLSchema#string

Stanislas Ropert

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sorafenib in advanced hepatocellular carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function.

Transection of the oesophagus for bleeding oesophageal varices.

Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis.

NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats.

P304

e16978

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0016978

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49854084

http://www.w3.org/2001/XMLSchema#string

P698

21340026

http://www.w3.org/2001/XMLSchema#string

P932

3038868

http://www.w3.org/2001/XMLSchema#string